Member Info for VincentVega

@oapk

Hitman?

Hi Brondby,

I don’t do twitter/x or Facebook.

Are you able to post the full transcript of that message please.

VV

Tech,

According to AS, China was investing millions in setting up a subsidiary company solely for the purposes of rolling out our tech. This was also the reason he gave for the lower royalty of 10%.

I’m all for running a tight ship and not announcing fluff, but there is a limit to a mushroom’s patience.

Just saying.

VV

A fantastic driving experience.

Whilst we are on the subject of disappointments and excitement.

AS was excited, along with me, to announce the following back in Nov 2022…

The new MOU reflects progress by iCCAMT to implement a clinical pilot study to evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer. The initial pilot clinical studies will be conducted at the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China.  These results will have the potential to provide a platform for developing full commercial tests that can be made available throughout China.

However, Ive been disappointed in the radio silence regarding China ever since.

Many thanks.👍

@Greend

Thanks for sharing.

What was the content of your initial email?

VV

I recall stating a little while back (on the dark side) that AS should have sold some shares at $7 as a hedge as it had been lower for a little while. This could have given us a 1 year runway and removed the subsequent share overhang.

Even though he stated in his interview that he likes the flexibility of owning the CDT shares, his follow on comments left me with the impression that he views it more of a longer term investment than a more immediate route to funding.

So if I had to call it then I’d say he’ll go the drawdown route this year.

I’d love him to prove my gut feel wrong though.

VV

I forgot to add the friendly elephant in the room.

No need for names, methinks.

VV

Hi Brondy,

It would be excellent news if we had our LDT ready for market in the 1st half of this year. In order to achieve this I estimate that successful clinical trials would need to be announced at the latest by the end of March 2024. Once completed we would then need to apply for an insurance reimbursement code to cover Medicare, Medicaid and any private payors.

If we take OBD as the most recent example, it took 3mths from application to delivery of their reimbursement code, enabling them to receive payments for tests carried out. Therefore, if we use March end as the expected trial results on date then we could begin paid-for tests in July.

With regards funding, the Company had £451k cash at 30th June 2023.

Now given that this is a new product and we are operating from a standing start even with any pre-work and marketing that Bill Behnke may have carried out with potential decision makers/end users (en masse) it will take time to achieve any meaningful traction that converts itself into the required revenue to rule out funding from outside sources. (500k pre-agreement or CDT sales)

Therefore, I foresee at least one fairly decent sized funding round this year and realistically one more early next year before we can get sight of break even and then free cash flow.

This of course is supposition on my part as there are quite a few unknown factors such as the price charged for each test and revenues from companion diagnostics, reagents and monoclonal antibodies, etc.

So if these funding events do transpire, I personally won’t see them as a surprise.

GL all

VV

Hi OAPK,

I’m not overly sure about how technical considerations will play a part in future movements here. We’ve had the “Golden Cross” which seemed to fizzle out.

We’ve also had a run of buying before, which has had a positive impact on the sp, only to retrace back to around the 2p level. This has happened on many occasions.

I think we are now, and have been for some time at a crossroads as far as the business and sp is concerned. A leak, outside influences and or news on the LDT are what will move this now.

I may be wrong, as I often am, but that’s how I see this now more than ever before.

I’ve followed suit. Both consigned to the green coffin.

You think that’s bad, lodgeview/dogger have spent all weekend on here and ADVFN.

Get a life fellas, there’s so much to see out in the real world.

As I said soonbetime, nobody can be 100% certain on the current trial status.

If we were to base our outlook on what has been said in Previous RNSs, then one would deduce that the trials in China started some time ago after it was stated that reagents would be delivered in Q2 2022. This would allow for an initial pilot trial of 300 patients.

Also in one of ASs interviews he stated that he was visiting our Chinese partners around Xmas 2022 and he looked forward to reporting back on progress over there.

Nothing came of either examples.

I quoted the Bio-Techne scenario to highlight how AS updates the market on milestones reached, but if we are to base progress on what has previously been said, then we are in the opinions business as shareholders.

I look forward to announcements on all fronts, and yes, even China.

Do I consider a trial start date as fluff?

No most certainly not.

GL all

VV

Soonbetime,

Unfortunately, there is nobody on here that is able to answer that question with 100% certainty.

Our CEO has gone on record as stating that he won’t announce “Fluff” news.

The platform trials with Bio-Techne as an example were only announced once they were completed.

The quandary therefore is either our CEO determines that announcing the start of the trials is fluff, or they haven’t actually started the trials yet.

My own view is that the start of the trials is material news which certainly cannot be categorised as anything other than material.

I know that this won’t answer your question, but that’s where we find ourselves.

VV

@Mary

I normally don’t wish losses on any retail investor, but a SDRY event would please me no end as it would knock dogger and his sidekick topaz clean off their perch.

Https://news.sky.com/story/cancer-survival-progress-in-uk-slower-than-it-has-been-for-50-years-report-says-13061458

I can confirm dogger posts under the name lodgeview on ADVFN.

CA not EC.

Oops.

Thanks for your response Brondby.

It would be good to hear something on the NHS, after an update on the US.

I feel that if we do hear anything regarding the NHS it would have to be some sort of agreement with the likes of Siemens or Abbott regarding initial work on fitting our IP onto their proprietary platforms. This would then allow them to carry out the necessary clinical trials to gain EC and or MHRA approval.

Not sure how long that would take, but I suspect that it would be measured in years, not months.

This would fit in with AS’s licensing model.

Hi Brondby,

I’d be interested to hear what sort of update your thinking of regarding the NHS.

VV